MX2017010837A - Dosis y metodos para administrar telavancina. - Google Patents
Dosis y metodos para administrar telavancina.Info
- Publication number
- MX2017010837A MX2017010837A MX2017010837A MX2017010837A MX2017010837A MX 2017010837 A MX2017010837 A MX 2017010837A MX 2017010837 A MX2017010837 A MX 2017010837A MX 2017010837 A MX2017010837 A MX 2017010837A MX 2017010837 A MX2017010837 A MX 2017010837A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- telavancin
- doses
- patient
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se divulgan dosis y métodos para administrar telavancina o una sal farmacéuticamente aceptable de la misma a un paciente humano que tiene una infección causada por Staphylococcus aureus, tal como bacteriemia, neumonía, endocarditis, osteomielitis, una infección de prótesis articular, o una infección complicada en la piel y la estructura de la piel. También se divulgan métodos para tratar una infección causada por Staphylococcus aureus en un paciente humano usando telavancina o una sal farmacéuticamente aceptable de la misma. La dosis de telavancina administrada al paciente es determinada, en parte, por el peso y la depuración de creatinina del paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119592P | 2015-02-23 | 2015-02-23 | |
| PCT/US2016/018396 WO2016137806A2 (en) | 2015-02-23 | 2016-02-18 | Doses and methods of administering telavancin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010837A true MX2017010837A (es) | 2017-12-07 |
Family
ID=55487131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010837A MX2017010837A (es) | 2015-02-23 | 2016-02-18 | Dosis y metodos para administrar telavancina. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160243190A1 (es) |
| EP (1) | EP3261658B8 (es) |
| JP (1) | JP2018505910A (es) |
| KR (1) | KR20170123650A (es) |
| CN (1) | CN107257689A (es) |
| AU (1) | AU2016223090A1 (es) |
| BR (1) | BR112017017883A2 (es) |
| CA (1) | CA2976384A1 (es) |
| EA (1) | EA201791895A1 (es) |
| HK (1) | HK1245644B (es) |
| IL (1) | IL253791A0 (es) |
| MX (1) | MX2017010837A (es) |
| TN (1) | TN2017000358A1 (es) |
| TW (1) | TW201639590A (es) |
| WO (1) | WO2016137806A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| CN113035369B (zh) * | 2021-03-10 | 2021-12-03 | 浙江大学 | 一种肾移植抗感染药物剂量预测模型的构建方法 |
| US20240024411A1 (en) * | 2021-11-24 | 2024-01-25 | Cumberland Pharmaceuticals Inc. | Methods for the prevention or treatment of anthrax infection |
| WO2023171588A1 (ja) * | 2022-03-08 | 2023-09-14 | 国立大学法人大阪大学 | 抗菌薬を含有するｐｌｇａ製剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI275594B (en) | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| TWI233932B (en) | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
| TWI312785B (en) | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| TWI342312B (en) | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| TWI641372B (zh) | 2013-03-15 | 2018-11-21 | 美商梅琳塔有限責任公司 | 使用抗生素治療超重和肥胖患者感染的方法 |
-
2016
- 2016-02-18 US US15/046,664 patent/US20160243190A1/en not_active Abandoned
- 2016-02-18 CA CA2976384A patent/CA2976384A1/en not_active Abandoned
- 2016-02-18 CN CN201680011698.4A patent/CN107257689A/zh active Pending
- 2016-02-18 EP EP16708853.3A patent/EP3261658B8/en active Active
- 2016-02-18 EA EA201791895A patent/EA201791895A1/ru unknown
- 2016-02-18 KR KR1020177026865A patent/KR20170123650A/ko unknown
- 2016-02-18 TN TNP/2017/000358A patent/TN2017000358A1/en unknown
- 2016-02-18 MX MX2017010837A patent/MX2017010837A/es unknown
- 2016-02-18 AU AU2016223090A patent/AU2016223090A1/en not_active Abandoned
- 2016-02-18 JP JP2017544316A patent/JP2018505910A/ja active Pending
- 2016-02-18 BR BR112017017883A patent/BR112017017883A2/pt not_active Application Discontinuation
- 2016-02-18 WO PCT/US2016/018396 patent/WO2016137806A2/en active Application Filing
- 2016-02-23 TW TW105105285A patent/TW201639590A/zh unknown
-
2017
- 2017-08-02 IL IL253791A patent/IL253791A0/en unknown
-
2018
- 2018-04-04 US US15/945,126 patent/US10751383B2/en active Active
- 2018-04-18 HK HK18105050.6A patent/HK1245644B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA201791895A1 (ru) | 2018-01-31 |
| CA2976384A1 (en) | 2016-09-01 |
| BR112017017883A2 (pt) | 2018-07-17 |
| HK1245644B (zh) | 2019-12-06 |
| EP3261658B8 (en) | 2019-06-05 |
| KR20170123650A (ko) | 2017-11-08 |
| CN107257689A (zh) | 2017-10-17 |
| IL253791A0 (en) | 2017-09-28 |
| EP3261658B1 (en) | 2019-04-03 |
| US10751383B2 (en) | 2020-08-25 |
| TW201639590A (zh) | 2016-11-16 |
| WO2016137806A3 (en) | 2016-10-20 |
| WO2016137806A2 (en) | 2016-09-01 |
| US20180236027A1 (en) | 2018-08-23 |
| AU2016223090A1 (en) | 2017-08-24 |
| EP3261658A2 (en) | 2018-01-03 |
| TN2017000358A1 (en) | 2019-01-16 |
| US20160243190A1 (en) | 2016-08-25 |
| JP2018505910A (ja) | 2018-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| BR112016003229A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| EP4378524A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
| MX2014004814A (es) | Compuestos y metodos para mejorar las respuestas inmunes innatas. | |
| MX2017010837A (es) | Dosis y metodos para administrar telavancina. | |
| HRP20211824T1 (hr) | Modulatori aktivnosti komplementa | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| TW201613578A (en) | Pharmaceutical combinations | |
| EA201792566A1 (ru) | Замещенные фенилоксазолидиноны для антимикробной терапии | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| MX2015016750A (es) | Composicion inmunogenica para uso en terapia. | |
| MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| EA201590350A1 (ru) | Комбинации с пептидом с циклизованной основной цепью | |
| BR112021018219A2 (pt) | Método de tratamento de endocardite infecciosa | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca |